Repligen (NASDAQ:RGEN) (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.
The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins. Repligen also produces single-use filtration devices and XCell ATF (alternating tangential flow) systems, which are used to improve cell culture performance and scalability. These products are integrated into manufacturing workflows by contract development and manufacturing organizations, academic research centers and global biopharmaceutical firms.
Over its history, Repligen has expanded through strategic acquisitions and internal product development to broaden its bioprocessing platform. Notable additions include the acquisitions of TangenX for flat-sheet filtration technology and the chromatography resin business from Novasep, enhancing its geographic footprint and product diversity. This growth strategy has enabled Repligen to offer end-to-end solutions from early-stage process development through commercial-scale production.
Repligen serves customers across North America, Europe and Asia, operating manufacturing and research facilities to support a global client base. Under the leadership of President and CEO Matthew Scullin, the company continues to invest in innovation, scaling its operations to meet the evolving demands of the biopharmaceutical industry while maintaining a focus on product quality and customer support.
